Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320

Thursday, September 6, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

WEST BRIDGEWATER, Mass., Sept. 5 PressureBioSciences, Inc. (Nasdaq: PBIO) today announced that it has received approvalto CE Mark the Barocycler NEP2320, a patent-pending, lightweight, compressedair driven pressure cycling technology (PCT) instrument. The Company alsoannounced that it has been issued a CB Scheme Test Certificate and Reportindicating that the Barocycler NEP2320 has been found in compliance with theIEC 61010-1 international standard applicable to safety requirements forelectrical equipment for measurement, control, and laboratory use.

The NEP2320 is the second PCT-based instrument for which PBI has receivedCE Marking approval and CB Scheme compliance. On May 1, 2007, the Companyannounced approval and compliance for the Barocycler NEP3229, the currentcenterpiece of its PCT Sample Preparation System (PCT SPS).

Dr. Nathan P. Lawrence, Vice President of Marketing and Sales for PBI,said: "We are very pleased to have received CE Mark approval and IEC 61010-1compliance for the Barocycler NEP2320. With approvals and compliance now inhand for both instruments of the PCT SPS, we now plan to accelerate ourefforts toward reaching our goal of initiating international commercializationof the PCT Sample Preparation System in 2008. To that end, we have meetingsscheduled over the next six weeks with our current distributors in France andJapan, and with potential distributors in Germany, Australia, and South Korea,all of whom have been anxiously awaiting our CE Mark and IEC 61010-1approvals. In addition to these meetings, we also plan to immediately seekadditional distributors for the PCT SPS in other countries around the world,especially in Europe and Asia."

About the Barocycler NEP2320

The NEP2320 offers a similar "look and feel" to the NEP3229, but has asystem weight of approximately 75 verses 350 pounds, and processes one sampleat a time, verses three for the NEP3229. Originally designed to be ademonstration unit for the larger NEP3229, the Company's market researchsuggested that there may be a niche in genomics and proteomics researchlaboratories for a Barocycler instrument with a lower sample throughput and alower price, but with many of the technical capabilities of the higherthroughput Barocycler NEP3229. Increasing European interest in PCT and thePCT SPS over the past several months has helped confirm the Company's initialmarket research findings.

About CE Mark and IEC 61010-1 Compliance

The CE Mark is a mandatory European marking for certain products toindicate conformity with the essential health, safety, and environmentalrequirements detailed in European Directives. With the approval to CE Markits Barocycler NEP2320, Pressure BioSciences (PBI) can now market thisinstrument to all countries within the European Union, as well as to countriesin other parts of the world that accept the CE Mark.

The CB Scheme is an international program for the exchange and acceptanceof product safety test results among participating laboratories andcertification organizations. The CB Scheme process offers mutual recognitionof test results among participating countries, normally without the need foradditional testing. The issuance of the CB Scheme Test Certificate and Report,indicating that the Barocycler NEP2320 has met the requirements of the IEC61010-1 international standard, is another important step in PBI's efforts tocommercialize and market the Barocycler NEP2320 to a number of countriesworldwide, including some that do not accept the CE Mark.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused onthe development of a novel, enabling technology called Pressure CyclingTechnology (PCT). PCT uses cycles of hydrostatic pressure between ambient andultra-high levels (up to 35,000 psi and greater) to control bio-molecularinteractions. PBI current

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store